Sleep Apnea and Bruxism Habitual Snoring

Total Page:16

File Type:pdf, Size:1020Kb

Sleep Apnea and Bruxism Habitual Snoring CAPD/ACDP Montreal 2014‐09‐13 Sleep disordered breathing (SDB) Occasional snoring Sleep apnea and bruxism Habitual snoring CAPD-ACDP 2014 Annual Meeting, Montreal Upper airway resistance syndrome Sleep apnea Increasing upper airway collapsibility airway upper Increasing Andrée Montpetit, DMD, MSc, RCDC Nelly Huynh, PhD Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation [email protected] [email protected] Snoring vibration of respiratory structures and the resulting sound, due to obstructed air movement while breathing during sleep. Obstructive Sleep Apnea (OSA) « characterized by repetitive episodes of complete (apnea) or partial (hypopnea) upper airway obstruction occurring during sleep. These events often result in reductions in blood oxygen saturation and are usually terminated by brief arousals from sleep. » Central Sleep Apnea « characterized on the polysomnogram by recurrent cessation off respiration during sleep with the apnea having no associated ventilatory effort. » Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Sleep study Epidemiology • Snoring Mild Moderate Severe • 3% to 12% 25% 5 to 15 events/hr 15 to 30 events/hr more than 30 events/hr Habitual snoring ??? • Sleep apnea AHI ≥ 10 and over is treated if SLEEPINESS and HBP • 1% to 10% 2% Huynh et al. 2012 AJODO Mild Moderate Severe 1 to 5 events/hr 5 to 10 events/hr more than 10 events/hr 34% mouth breathers Habitual snoring abnormal Clinically significant ≥5/hr due to study on elevated BP [Bixler 2008] • Prevalence peak between 2-8 y.o. [Fujioka 1979, Jeans 1981, Sahin 2009] Dayyat 2007; AASM 2005 Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation 1 CAPD/ACDP Montreal 2014‐09‐13 Seasonal incidence Consequences As early as perinatal period • Woman with OSA have increased risks for: • 1.8% for low birth weight • 2.3% for preterm birth • 1.3% for small size for gestational age • 1.7% for cesarian section • 1.6% for preeclampsia/eclampsia Chen et al. 2012 Am J Obstet Gynecol Walter et al. 2013 Arch Dis Child Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Consequences Can SDB grow an ADHD child? Cardiovascular Metabolism Growth Cognition Hypoxic stress Growth delay Controversial ↓ ↑sympathetic activation Growth catch-up Execute functions ↓ after T&A and behavior Insulin resistance (Type 2 Diabetes) ↑ ↑nocturnal cortisol Following treatment: ↑ Hypersomnolence Constantin et al., 2014 Behav Sleep Med ↓ TNF-α [Montgomery-Downs 2010; Ungkanont 2006; Liu 2005, (inflammatory Nimubona 2000; • By 4 y.o., children with mouthbreathing, snoring and/or witnessed apnea were cytokines) Trachtenbard 1998; [Lewin 2002, O’Brien 2004, Commare 1993; Breton Beebe 2004, Halbower 2006, 20-60% more likely to exhibit behavioral difficulties consistent with clinical dx. 1993; Stradling 1990] Honaker 2009, Calhoun 2009, [Kiris 2010; Aydogan 2007; Kohler 2009, Sahin 2009, [Gozal 2010] Bar 1999] Ting 2010] • By 7 y.o., they were 40-100% more likely. Bonnuck et al., 2012 Pediatr Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Consequence – mortality in adults Risk factors Children Adults Although there is no 1. Nasal obstruction 1. Obesity available data in children, 2. Skeletal morphology 2. Nasal obstruction untreated apnea leads to 3. Soft tissues 3. Skeletal morphology greater mortality in 4. Obesity 4. Soft tissues adults. 5. Familial predisposition 5. Familial predisposition Growth Aging He et al., 1988 Chest Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation 2 CAPD/ACDP Montreal 2014‐09‐13 Nasal obstruction Risk factors Children Adults • Seasonal allergic rhinitis • Deviated septum 1. Nasal obstruction 1. Obesity • Hypertrophy of turbinates 2. Skeletal morphology 2. Nasal obstruction 3. Soft tissues 3. Skeletal morphology 4. Obesity 4. Soft tissues 5. Familial predisposition 5. Familial predisposition Growth Aging Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s rôleClinicalTreatments Evaluation PANIC study PANIC study • 6-8 years old with • 6-8 years old with and without SDB and without SDB • Questionnaires • Questionnaires • Abnormal palatal morphology (Mallampati III or IV) • Thick neck • Adipose tissue under the chin • Abnormal craniofacial morphology, but not excess • Cross bite body fat, is associated with an increased risk of having • Open bite SDB in 6-8-year-old children • Convex facial profile • Increased lower facial height • Mandibular retrusion • Tonsilar hypertrophy Ikavalko et al., 2012 Ikavalko et al., 2012 Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Craniofacial morphology Craniofacial morphologies in children with OSA • Strong association between OSA and congenital craniofacial malformations Risk factors Authors Studies • Mandibular hypoplasia Marino 21 OSA pts (mean age 4.5 y.o.) • Pierre-Robin 2009 Ceph Long and narrow face • Prader-Willi • Treacher-Collins Pirila- 41 OSA pts (mean age 7.2 y.o.) vs Narrow width • Marfant Parkkinen 41 controls 2009 Dental casts (high arch palate, narrow maxillary) Pirila- • Maxillary hypoplasia 70 snorers/symptomatic OSA pts, Parkkinen • Down syndrome 70 controls (mean age 7.2 y.o.) • Cleft palate 2010 Mandibular • Apert, Crouzon or Pfeiffer syndromes Tsuda 173 children (20% strong snorers) retrognatia 2010 OSA-18 and ceph Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation 3 CAPD/ACDP Montreal 2014‐09‐13 Predisposing factors/risks Risk factors Children Adults 1. Nasal obstruction 1. Obesity 2. Skeletal morphology 2. Nasal obstruction Sleep Craniofacial disordered 3. Soft tissues 3. Skeletal morphology imbalances breathing 4. Obesity 4. Soft tissues 5. Familial predisposition 5. Familial predisposition Growth Aging Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Soft tissues - airway Age – tonsils and adenoids Controls OSA • Narrowest at A+T • In snoring children: T&A hypertrophy persists A – adenoids; T – tonsils; A+T – overlap; E – epiglottis Arens et al. 2003 Papaioannou et al. 2013 J Pediatr MécanismesMechanisms RisquesRisksSymptomsSymptômesSymptomsTreatmentsTraitementsScreeningRoleRôle of duDentist dentisteDentist’s roleClinicalÉvaluationTreatments Evaluation clinique MécanismesMechanisms RisquesRisksSymptomsSymptômesSymptomsTreatmentsTraitementsScreeningRoleRôle of duDentist dentisteDentist’s roleClinicalÉvaluationTreatments Evaluation clinique Soft tissues Macroglossy • Tonsils • Often in association with a syndrome • classification: 4 CAPD/ACDP Montreal 2014‐09‐13 Soft tissues Airway obstruction from soft tissues • Long soft palate Risk factors Obesity Children Adults • Obese children have a (4.5x) increased risk of developing obstructive sleep apnea [Redline 1999] 1. Nasal obstruction 1. Obesity 2. Skeletal morphology 2. Nasal obstruction • Incidence of SDB: 3. 3. Soft tissues Skeletal morphology • Obese children– 46% [Marcus 1996] 4. Obesity 4. Soft tissues • Morbidly obese children– 55% [Kalra 2005] 5. Familial predisposition 5. Familial predisposition • Possible causes: • Adipose tissue deposited in pharyngeal Growth Aging area (fat pads) [Shelton 1993, Schwab 2003] Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation MécanismesMechanisms• TissusRisquesRisks SymptomsadipeuxSymptômesSymptomsTreatments TraitementsviscéralScreeningRole Rôle[Vgontzas of duDentist dentisteDentist’s 2008, Makino roleClinicalÉvaluation 2009] Treatments Evaluation clinique Risk factors Breastfeeding and snoring Children Adults 1. Nasal obstruction 1. Obesity 2. Skeletal morphology 2. Nasal obstruction 3. Soft tissues 3. Skeletal morphology 4. Obesity 4. Soft tissues 5. Familial predisposition 5. Familial predisposition • Breastfeeding for at least one month reduced the risk of parent reported snoring and witnessed apneas. Growth Aging • In this study, no children breastfed more than 3 month had witnessed apneas at age 8. Brew et al. 2014 PLOS one Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s roleClinicalTreatments Evaluation Mechanisms RisksSymptomsSymptomsTreatmentsScreeningRole of DentistDentist’s
Recommended publications
  • Sleep Disturbance in MS
    SLEEP DISTURBANCE AND MULTIPLE SCLEROSIS Abbey J. Hughes, PhD Department of Rehabilitation Medicine University of Washington School of Medicine Table of Contents Introduction ................................................................................................................................................................ 2 Summary of MS Sleep Research .......................................................................................................................... 3 Emerging Treatments for Sleep Disturbance in MS .................................................................................... 6 Tips for Assessing Your Sleep – Worksheet .................................................................................................. 8 Additional Tools and Resources.......................................................................................................................... 9 References ................................................................................................................................................................ 10 1 Introduction Multiple sclerosis (MS) is a chronic disease characterized by loss of myelin (demyelination) and damage to nerve fibers (neurodegeneration) in the central nervous system (CNS). MS is associated with a diverse range of physical, cognitive, emotional, and behavioral symptoms, and can significantly interfere with daily functioning and overall quality of life. MS directly impacts the CNS by causing demyelinating lesions, or plaques, in the brain,
    [Show full text]
  • 2 ? Obesity and Sleep- Disordered Breathing
    Review series Obesity and the lung: 2 ? Obesity and sleep- Thorax: first published as 10.1136/thx.2007.086843 on 28 July 2008. Downloaded from disordered breathing F Crummy,1 A J Piper,2 M T Naughton3 1 Regional Respiratory Centre, ABSTRACT include excessive daytime sleepiness, unrefreshing Belfast City Hospital, Belfast, 2 As the prevalence of obesity increases in both the sleep, nocturia, loud snoring (above 80 dB), wit- UK; Royal Prince Alfred developed and the developing world, the respiratory nessed apnoeas and nocturnal choking. Signs Hospital, Woolcock Institute of Medical Research, University of consequences are often underappreciated. This review include systemic (or difficult to control) hyperten- Sydney, Sydney, New South discusses the presentation, pathogenesis, diagnosis and sion, premature cardiovascular disease, atrial fibril- Wales, Australia; 3 General management of the obstructive sleep apnoea, overlap and lation and heart failure.8 The obstructive sleep Respiratory and Sleep Medicine, obesity hypoventilation syndromes. Patients with these apnoea syndrome (OSAS) is arbitrarily defined by Department of Allergy, Immunology and Respiratory conditions will commonly present to respiratory physi- .5 apnoeas or hypopnoeas per hour plus symp- Medicine, Alfred Hospital and cians, and recognition and effective treatment have toms of daytime sleepiness. Monash University, Melbourne, important benefits in terms of patient quality of life and Almost 20 years ago the prevalence of OSA and Victoria, Australia reduction in healthcare
    [Show full text]
  • Respiratory Mechanics and Ventilatory Control in Overlap Syndrome and Obesity Hypoventilation Johan Verbraecken1* and Walter T Mcnicholas2,3
    Verbraecken and McNicholas Respiratory Research 2013, 14:132 http://respiratory-research.com/content/14/1/132 REVIEW Open Access Respiratory mechanics and ventilatory control in overlap syndrome and obesity hypoventilation Johan Verbraecken1* and Walter T McNicholas2,3 Abstract The overlap syndrome of obstructive sleep apnoea (OSA) and chronic obstructive pulmonary disease (COPD), in addition to obesity hypoventilation syndrome, represents growing health concerns, owing to the worldwide COPD and obesity epidemics and related co-morbidities. These disorders constitute the end points of a spectrum with distinct yet interrelated mechanisms that lead to a considerable health burden. The coexistence OSA and COPD seems to occur by chance, but the combination can contribute to worsened symptoms and oxygen desaturation at night, leading to disrupted sleep architecture and decreased sleep quality. Alveolar hypoventilation, ventilation-perfusion mismatch and intermittent hypercapnic events resulting from apneas and hypopneas contribute to the final clinical picture, which is quite different from the “usual” COPD. Obesity hypoventilation has emerged as a relatively common cause of chronic hypercapnic respiratory failure. Its pathophysiology results from complex interactions, among which are respiratory mechanics, ventilatory control, sleep-disordered breathing and neurohormonal disturbances, such as leptin resistance, each of which contributes to varying degrees in individual patients to the development of obesity hypoventilation. This respiratory embarrassment takes place when compensatory mechanisms like increased drive cannot be maintained or become overwhelmed. Although a unifying concept for the pathogenesis of both disorders is lacking, it seems that these patients are in a vicious cycle. This review outlines the major pathophysiological mechanisms believed to contribute to the development of these specific clinical entities.
    [Show full text]
  • Insomnia in Adults
    New Guideline February 2017 The AASM has published a new clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. These new recommendations are based on a systematic review of the literature on individual drugs commonly used to treat insomnia, and were developed using the GRADE methodology. The recommendations in this guideline define principles of practice that should meet the needs of most adult patients, when pharmacologic treatment of chronic insomnia is indicated. The clinical practice guideline is an essential update to the clinical guideline document: Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349. SPECIAL ARTICLE Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults Sharon Schutte-Rodin, M.D.1; Lauren Broch, Ph.D.2; Daniel Buysse, M.D.3; Cynthia Dorsey, Ph.D.4; Michael Sateia, M.D.5 1Penn Sleep Centers, Philadelphia, PA; 2Good Samaritan Hospital, Suffern, NY; 3UPMC Sleep Medicine Center, Pittsburgh, PA; 4SleepHealth Centers, Bedford, MA; 5Dartmouth-Hitchcock Medical Center, Lebanon, NH Insomnia is the most prevalent sleep disorder in the general popula- and disease management of chronic adult insomnia, using existing tion, and is commonly encountered in medical practices. Insomnia is evidence-based insomnia practice parameters where available, and defined as the subjective perception of difficulty with sleep initiation, consensus-based recommendations to bridge areas where such pa- duration, consolidation, or quality that occurs despite adequate oppor- rameters do not exist.
    [Show full text]
  • Xyrem (Sodium Oxybate) Is a CNS Depressant
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Important Administration Information for All Patients XYREM safely and effectively. See full prescribing information for • Take each dose while in bed and lie down after dosing (2.3). XYREM. • Allow 2 hours after eating before dosing (2.3). • Prepare both doses prior to bedtime; dilute each dose with approximately ¼ XYREM® (sodium oxybate) oral solution, CIII cup of water in pharmacy-provided containers (2.3). Initial U.S. Approval: 2002 • Patients with Hepatic Impairment: starting dose is one-half of the original dosage per night, administered orally divided into two doses (2.4). • WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION Concomitant use with Divalproex Sodium: an initial reduction in Xyrem dose and ABUSE AND MISUSE. of at least 20% is recommended (2.5, 7.2). --------------------DOSAGE FORMS AND STRENGTHS------------------- See full prescribing information for complete boxed warning. Oral solution, 0.5 g per mL (3) Central Nervous System Depression ----------------------------CONTRAINDICATIONS------------------------------ • Xyrem is a CNS depressant, and respiratory depression can occur with • In combination with sedative hypnotics or alcohol (4) Xyrem use (5.1, 5.4) • Succinic semialdehyde dehydrogenase deficiency (4) Abuse and Misuse • Xyrem is the sodium salt of gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB is associated with CNS adverse reactions, ---------------------WARNINGS AND PRECAUTIONS----------------------
    [Show full text]
  • Nocturia: the Complex Role of the Heart, Kidneys, and Bladder
    EUF-773; No. of Pages 3 E U R O P E A N U R O L O G Y F O C U S X X X ( 2 0 1 9 ) X X X – X X X ava ilable at www.sciencedirect.com journa l homepage: www.europeanurology.com/eufocus Mini Review – Voiding Dysfunction Nocturia: The Complex Role of the Heart, Kidneys, and Bladder a,* a b Riccardo Lombardo , Andrea Tubaro , Fiona Burkhard a b Ospedale Sant’ Andrea, Sapienza University of Rome, Rome, Italy; Department of Urology, Inselspital University Hospital Bern, Bern, Switzerland Article info Abstract Article history: We review the role of the heart, kidneys, and bladder in the pathophysiology of nocturia Accepted July 25, 2019 and nocturnal polyuria. Lower urinary tract symptoms such as nocturia have often been associated with lower urinary tract dysfunction. It is known that the bladder contributes Associate Editor: to nocturia in the case of low functional capacity, urgency, and detrusor overactivity. Heart diseases, especially arterial hypertension and congestive heart failure, are closely Malte Rieken related to nocturnal polyuria. The main mechanisms include renal hyperfiltration and elevated atrial natriuretic peptide. A number of drugs frequently used in cardiovascular Keywords: disorders are implicated in nocturia; diuretics, calcium channel blockers, and b-blockers Nocturia induce nocturnal polyuria and thus nocturia, whereas alpha-blockers improve nocturia. Among the different forms of hypertension, nondipping arterial hypertension has been Nocturnal polyuria associated with a higher risk of nocturnal polyuria. Besides the role of the kidneys in Physiopathology nocturia linked to arterial hypertension, chronic kidney disease is an independent predictor of nocturia through an osmotic diuresis mechanism.
    [Show full text]
  • Circadian Rhythm Abnormalities
    Review Article Address correspondence to Dr Phyllis C. Zee, Northwestern University, 710 North Lake Circadian Rhythm Shore Dr, Chicago, IL 60611, [email protected]. Relationship Disclosure: Abnormalities Dr Zee has received personal compensation for activities Phyllis C. Zee, MD, PhD; Hrayr Attarian, MD, FAASM, FCCP; with Jazz Pharmaceuticals; Merck & Co, Inc; Perdue Aleksandar Videnovic, MD, MSc Pharma; Philips Respironics; Sanofi-Aventis; Takeda Pharmaceutical Company Limited; UCB; and Zeo, Inc. ABSTRACT Dr Zee receives research Purpose: This article reviews the recent advances in understanding of the funda- support from Philips mental properties of circadian rhythms and discusses the clinical features, diagnosis, Respironics. Dr Attarian receives personal and treatment of circadian rhythm sleep disorders (CRSDs). compensation for activities Recent Findings: Recent evidence strongly points to the ubiquitous influence of with American Physicians circadian timing in nearly all physiologic functions. Thus, in addition to the prominent Institute. Dr Videnovic reports no disclosure. sleep and wake disturbances, circadian rhythm disorders are associated with cognitive Unlabeled Use of impairment, mood disturbances, and increased risk of cardiometabolic disorders. The Products/Investigational recent availability of biomarkers of circadian timing in clinical practice has improved Use Disclosure: Dr Zee discusses the unlabeled use of our ability to identify and treat these CRSDs. melatonin for the treatment of Summary: Circadian rhythms are endogenous rhythms with a periodicity of circadian disorders. Dr Attarian approximately 24 hours. These rhythms are synchronized to the physical environment discusses the unlabeled use of melatonin and light boxes to by social and work schedules by various photic and nonphotic stimuli. CRSDs result advance or delay circadian from a misalignment between the timing of the circadian rhythm and the external rhythms.
    [Show full text]
  • Nocturia Table of Contents
    Information for Patients English Nocturia Table of contents What is nocturia? ............................................................................................................ 3 How common is nocturia? .......................................................................................... 3 What causes nocturia? ................................................................................................... 3 Diagnosis of nocturia .................................................................................................. 3 Medical history ....................................................................................................................... 4 Physical examination ........................................................................................................ 4 Bladder diary ............................................................................................................................ 4 Questionnaires ........................................................................................................................ 4 Treatment of nocturia ............................................................................................... 3 Over-the-counter supplements ............................................................................. 4 Muscarinic receptor antagonists ......................................................................... 4 Loop diuretics ..........................................................................................................................
    [Show full text]
  • Nocturia a Guide for Women 1
    Figure 1: Urinary Tract Nocturia A Guide for Women 1. What is nocturia? 2. What causes nocturia? 3. How is nocturia diagnosed? 4. How can nocturia be treated? 5. What is Nocturnal Polyuria Syndrome (NPS)? What is nocturia? Nocturia is a condition which causes you to awaken many • Bladder spasm/overactivity (as in overactive bladder, times (more than 2 times) during the night to urinate. This with or without urge urinary incontinence – see www. leads to sleep deprivation. Nocturia is more common as we yourpelvicfloor.org/conditions/overactive-bladder). age. • Bladder infection, recurrent infection, or inflamma- tion that causes the bladder wall to stiffen, often with shrinkage, irritation, and spasm. Eventually the bladder What causes nocturia? is unable to hold as much urine at night. Nocturia is generally caused by polyuria (an excessive or • Interstitial cystitis (Painful Bladder Syndrome – see abnormally large production of urine), low nighttime blad- www.yourpelvicfloor.org/conditions/interstitial- der capacity (not being able to hold enough in the bladder at cystitis), which can cause bladder pain, in turn leading night), or a combination of these. to the need to go to the toilet with greater frequency at night, just as it does during the day. Polyuria may be caused by: • Neurogenic bladder disorder, in which the nerve com- • High fluid intake, especially in the evening. municates abnormally to the bladder, causing abnormal filling and emptying. • Untreated or poorly controlled diabetes. High blood sugar can make you thirsty and the resulting high fluid intake leads to polyuria. How is nocturia diagnosed? • Congestive heart failure – a condition in which the heart Your healthcare provider will take a careful history, which does not pump blood through the body efficiently – can will include your medical history and any medications you result in a large amount of fluid gathering in the legs are taking.
    [Show full text]
  • Sleep Disorders
    Sleep Disorders FirstHealth of the Carolinas’ Sleep Disorders Centers provide clinically diagnostic sleep disorder assessments as well as therapeutic titration with CPAP, BiPAP, ASV and oxygen augmentation. The Sleep Disorders Centers are located in hospital settings and provide sleep studies for patients 4-years-old and above. Procedures performed require a provider’s order and face to face notes. All sleep studies are read and interpreted by a Board Certified Sleep Specialist. Patients of the Sleep Disorders Centers are given the option to follow up with their referring provider or the sleep specialist. Indications for a Sleep Study: Consequences of Untreated Scope of Services Provided: • Snoring Sleep Apnea: • Polysomnography • Witnessed apneas • High Blood Pressure • Split-night polysomnography • Waking up gasping or choking • Heart Attack • Multiple Sleep Latency Testing • Excessive daytime sleepiness • Stroke • Maintenance of Wakefulness Testing • Frequent naps • Depression • Titration Therapy with CPAP, BiPAP & ASV • Morning headaches • Diabetes • Home Sleep Testing • Insomnia • Obesity • Mask Desensitization • Disturbed sleep due to: • Falling asleep while driving - leg-kicking - nightmares - night terrors Moore County Main Phone Number: (910) 715-3338 Fax Number: (910) 715-5346 Address: 155 Memorial Drive • Pinehurst, NC 28374 Hoke County (Home Sleep Testing only) Main Phone Number: (910) 715-3338 Fax Number: (910) 715-5346 Address: 6408 Fayetteville Road • Raeford, NC 28376 Montgomery County Main Phone Number: (910) 571-5600
    [Show full text]
  • Nocturia and Night-Time Incontinence
    cmE caSE PrESENTaTION Nocturia and Night-Time Incontinence David r. staskin, MD LEarNINg ObjEcTIvES: Associate Professor of Urology 1. Discuss the definitions of Nocturia and Director, Female Urology and Male Voiding Dysfunction st. Elizabeth’s Medical center Night-Time Incontinence (N & NTI); tufts University school of Medicine, Boston, MA 2. Identify the etiology and pathophysiology of N and NTI; Disclosure record for David R. Staskin, M.D. 3. Evaluate the symptoms of N and NTI Last reviewed/edited this information on January 10, 2011. Uroplasty: Consultant or Advisor; American Medical Systems: and the differential diagnosis for these Consultant or Advisor; Astellas: Consultant or Advisor; symptoms; and Pfizer: Consultant or Advisor; Glaxo: Consultant or Advisor; Allergan: Consultant or Advisor 4. Describe appropriate treatment strategies for N and NTI into daily practice. PhysicIaN accreditation STatement PhysicIaN credit STatement The University of North Texas Health Science Center at Fort Worth Office of Professional The University of North Texas Health Science Center has requested that the AOA and Continuing Education is accredited by the American Osteopathic Association to Council on Continuing Medical Education approve this program for 1 hour of AOA award continuing medical education to physicians. Category 2B CME credits. Approval is currently pending. The University of North Texas Health Science Center at Fort Worth Office of The University of North Texas Health Science Center at Fort Worth designates this Professional and Continuing Education is accredited by the American Council for enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Continuing Medical Education (ACCME) to provide continuing medical education Physicians should claim only the credit commensurate with the extent of their for physicians.
    [Show full text]
  • Application for Inclusion of Fexinidazole in the Who Model List of Essential Medicines (Adult & Children)
    APPLICATION FOR INCLUSION OF FEXINIDAZOLE IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES (ADULT & CHILDREN) Date: 28-Nov-2018 Total number of pages: 45 Page 1 Application for inclusion in WHO Model List of Essential Medicines 28-Nov-2018 - fexinidazole TABLE OF CONTENTS TITLE PAGE ................................................................................................................................................... 1 TABLE OF CONTENTS .................................................................................................................................. 2 LIST OF TABLES ........................................................................................................................................... 4 LIST OF FIGURES .......................................................................................................................................... 4 ABBREVIATIONS ........................................................................................................................................... 5 1 SUMMARY STATEMENT OF THE PROPOSAL FOR INCLUSION .............................................. 6 2 RELEVANT WHO TECHNICAL DEPARTMENT AND FOCAL POINT (IF APPLICABLE) - NAME OF THE FOCAL POINT IN WHO SUBMITTING OR SUPPORTING THE APPLICATION. ................................................................................................................................ 7 3 NAME OF ORGANIZATION(S) CONSULTED AND/OR SUPPORTING THE APPLICATION ................................................................................................................................
    [Show full text]